Magnetic Resonance Macromolecular Agents for Monitoring Tumor Microvessels and Angiogenesis Inhibition
暂无分享,去创建一个
Gabriel P Krestin | Anda Preda | Robert C Brasch | R. Brasch | G. Krestin | Marion van Vliet | Cornelius F van Dijke | M. van Vliet | A. Preda | C. F. van Dijke
[1] E. Kahn,et al. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. , 2002, Academic radiology.
[2] Andrea Sbarbati,et al. Effect of Tamoxifen in an Experimental Model of Breast Tumor Studied by Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Different Contrast Agents , 2005, Investigative radiology.
[3] M. Port,et al. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[4] R W Günther,et al. Differentiation of spontaneous canine breast tumors using dynamic magnetic resonance imaging with 24-Gadolinium-DTPA-cascade-polymer, a new blood-pool agent. Preliminary experience. , 1996, Investigative radiology.
[5] Georg Breier,et al. Molecular Mechanisms of Developmental and Tumor Angiogenesis , 1994, Brain pathology.
[6] R. Dolan,et al. MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.
[7] G. Frija,et al. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. , 1993, Magnetic resonance imaging.
[8] Robert C. Brasch,et al. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[9] G. Adam,et al. Gd‐DTPA‐cascade‐polymer: Potential blood pool contrast agent for MR imaging , 1994, Journal of magnetic resonance imaging : JMRI.
[10] G. Adam,et al. Dynamic contrast‐enhanced MR imaging of the upper abdomen: Enhancement properties of gadobutrol, gadolinium‐DTPA‐polylysine, and gadolinium‐DTPA‐cascade‐polymer , 1994, Magnetic resonance in medicine.
[11] D M Shames,et al. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. , 2000, Academic radiology.
[12] N. van Bruggen,et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. , 1998, Cancer investigation.
[13] A. Padhani. MRI for assessing antivascular cancer treatments. , 2003, The British journal of radiology.
[14] T. Helbich,et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media--preliminary experience. , 1999, Radiology.
[15] D M Shames,et al. A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution , 1997, Magnetic resonance in medicine.
[16] C. Corot,et al. Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[17] M. Hynes,et al. Development of a novel nonaromatic small-molecule MR contrast agent for the blood pool. , 1998, Academic radiology.
[18] R. Brasch,et al. MRI monitoring of Avastin™ antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer , 2004, Journal of magnetic resonance imaging : JMRI.
[19] H. Schlemmer,et al. Dynamic Magnetic Resonance Tomography and Proton Magnetic Resonance Spectroscopy of Prostate Cancers in Rats Treated by Radiotherapy , 2004, Investigative radiology.
[20] Viktor Novikov,et al. Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights , 2004, Journal of magnetic resonance imaging : JMRI.
[21] R. Brasch,et al. Contrast-Enhanced Magnetic Resonance Imaging Estimation of Altered Capillary Permeability in Experimental Mammary Carcinomas After X-Irradiation , 1994, Investigative radiology.
[22] D M Shames,et al. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries , 1998, Magnetic resonance in medicine.
[23] P M Carpenter,et al. Characterization of N‐ethyl‐N‐nitrosourea‐induced malignant and benign breast tumors in rats by using three MR contrast agents , 1999, Journal of magnetic resonance imaging : JMRI.
[24] H. Weinmann,et al. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. , 1991, Investigative radiology.
[25] R. Brasch,et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model , 2001, Journal of magnetic resonance imaging : JMRI.
[26] T. Helbich,et al. A new polysaccharide macromolecular contrast agent for MR imaging: Biodistribution and imaging characteristics , 2000, Journal of magnetic resonance imaging : JMRI.
[27] J. Finn,et al. Three‐dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B‐22956/1 , 2001, Journal of magnetic resonance imaging : JMRI.
[28] R. Brasch,et al. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. , 2000, European journal of radiology.
[29] R. Brasch. New directions in the development of MR imaging contrast media. , 1992, Radiology.
[30] C. Corot,et al. Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA. A new paramagnetic dextran polymer. , 1997, Acta radiologica. Supplementum.
[31] S. H. Koenig,et al. 1H-NMRD and17O-NMR assessment of water exchange and rotational dynamics of two potential MRI agents: MP-1177 (an extracellular agent) and MP-2269 (a blood pool agent) , 1999, Magnetic Resonance Materials in Physics, Biology and Medicine.
[32] D M Shames,et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. , 2001, Radiology.
[33] D M Shames,et al. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: A quantitative noninvasive technique , 1993, Magnetic resonance in medicine.
[34] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[35] N Grenier,et al. Evaluation of Intrarenal Distribution of Ultrasmall Superparamagnetic Iron Oxide Particles by Magnetic Resonance Imaging and Modification by Furosemide and Water Restriction , 1994, Investigative radiology.
[36] M. Ogan,et al. Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. , 1987, Investigative radiology.
[37] P. Anelli,et al. Gadocoletic Acid Trisodium Salt (B22956/1): A New Blood Pool Magnetic Resonance Contrast Agent With Application in Coronary Angiography , 2006, Investigative radiology.
[38] Wolfgang Ebert,et al. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[39] Xiaobing Fan,et al. New model for analysis of dynamic contrast‐enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors , 2004, Magnetic resonance in medicine.
[40] T. Helbich,et al. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS‐325) with correlations to histopathology , 2001, Journal of magnetic resonance imaging : JMRI.
[41] Atle Bjørnerud,et al. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. , 2003, Radiology.
[42] R. Lauffer,et al. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. , 1997, Investigative radiology.
[43] O Nalcioglu,et al. Tumor characterization with dynamic contrast–enhanced MRI using mr contrast agents of various molecular weights , 1998, Magnetic resonance in medicine.
[44] D M Shames,et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. , 2000, American journal of obstetrics and gynecology.
[45] T. Roberts,et al. Physiologic measurements by contrast‐enhanced MR imaging: Expectations and limitations , 1997, Journal of magnetic resonance imaging : JMRI.
[46] N. van Bruggen,et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.
[47] I. Zuna,et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution , 2002, European Radiology.
[48] M. Hynes,et al. Synthesis and preliminary evaluation of MP‐2269: A novel, nonaromatic small‐molecule blood‐pool MR contrast agent , 1998, Magnetic resonance in medicine.
[49] V. Deshpande,et al. Comparison of Gradient-Echo and Steady-State Free Precession for Coronary Artery Magnetic Resonance Angiography Using a Gadolinium-Based Intravascular Contrast Agent , 2006, Investigative radiology.
[50] R. Brasch,et al. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. , 1996, Radiology.
[51] Hon J. Yu,et al. Measurement of Volumetric and Vascular Changes with Dynamic Contrast Enhanced MRI for Cancer Therapy Monitoring , 2002, Technology in cancer research & treatment.
[52] Robert C. Brasch,et al. Macromolecular contrast agents for MR mammography: current status , 2003, European Radiology.
[53] A Heerschap,et al. Fast dynamic gadolinium‐enhanced MR imaging of urinary bladder and prostate cancer , 1999, Journal of magnetic resonance imaging : JMRI.
[54] U Schmiedl,et al. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. , 1987, Radiology.
[55] M. Moseley,et al. Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: and experimental study in rats. , 1986, AJR. American journal of roentgenology.
[56] O. Haraldseth,et al. New intravascular contrast agent applied to dynamic contrast enhanced MR imaging of human breast cancer. , 2003, Acta radiologica.
[57] J. Hoffman,et al. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. , 2000 .
[58] D P Dearnaley,et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. , 2000, Clinical radiology.
[59] R. Brasch,et al. AUR Memorial Award 1991. Immunogenicity of gadolinium-based contrast agents for magnetic resonance imaging. Induction and characterization of antibodies in animals. , 1991, Investigative radiology.
[60] D C Peters,et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.
[61] O Nalcioglu,et al. Investigation of longitudinal vascular changes in control and chemotherapy‐treated tumors to serve as therapeutic efficacy predictors , 1999, Journal of magnetic resonance imaging : JMRI.
[62] Peter Caravan,et al. Species Dependence on Plasma Protein Binding and Relaxivity of the Gadolinium-Based MRI Contrast Agent MS-325 , 2006, Investigative radiology.
[63] R. Dolan,et al. First-pass renal perfusion imaging using MS-325, an albumin-targeted MRI contrast agent. , 1999, Investigative radiology.
[64] G Brix,et al. Multicompartment analysis of gadolinium chelate kinetics: Blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.
[65] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[66] D M Shames,et al. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology , 2001, Magnetic resonance in medicine.
[67] T. Woolsey,et al. Albumin‐binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model , 2003, Magnetic resonance in medicine.
[68] Angiogenesis imaging. , 2000, Academic radiology.
[69] R. Brasch,et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.
[70] D M Shames,et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. , 1998, AJR. American journal of roentgenology.